Preventing Preterm Problems
Researchers explore the use of small molecules to reduce the risk of preterm birth
Maryam Mahdi | | Quick Read
This article was published in our sister publication, The Small Molecule Manufacturer, which celebrates the field of small molecule drug development and manufacturing with interviews and articles focusing on success stories, equipment, and new processing techniques. Read more about The Small Molecule Manufacturer here https://themedicinemaker.com/manufacture/small-but-never-forgotten
Birth before 37 weeks of gestation accounts for 15 million deaths each year, but tocolytics – the drugs used to suppress labor – have limited use. “Currently there are no FDA-approved drugs that reliably halt spontaneous preterm labor (sPTL) – none of the most commonly used tocolytics can delay preterm birth beyond 48-hours,” says Scott Barnett, a researcher at the University of Nevada’s Reno School of Medicine. “This short reprieve, at best provides, a limited window to administer corticosteroids to help develop the infant’s lungs prior to birth.”
And so, with the aim of providing pregnant women with a more effective range of safe medicines, the Iain L.O. Buxton research group, of which Barnett is a senior postdoctoral fellow, has characterized a molecular pathway that contributes to the phenomenon of sPTL, and identified four drugs with the potential to prevent it (1).
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine